KJ 48th, @randyreg On another site (I do seem to end up in different spots on this website...), I discussed some current information offered by Eisai. Title is Eisai Presents New Data on the Continued and Expanding Benefits of LEB Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025. It gives "time savings" for those going from Mild (MCI) to Mild Alzheimer and also MCI to Moderate Alzheimer. It's easy to read format and is very encouraging for those of us "lucky enough" to be eligible for infusions (which, by the way, are on the way to becoming completely at home injections without having to wait the 18 months!!!Please, please keep abreast of all the innovative methods coming along for us.